Business
ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update
LYON, France, September 25, 2025--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces today its first half financial results for the six months period ended June 30th, 2025, and provides a business update.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/fe887767fbf99f83398c5ca3e42b4b6f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jq31yNCQ9hMzsYXEG3rMIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/fe887767fbf99f83398c5ca3e42b4b6f","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/b5bqzFijj2XPzYJKiWbJWQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/fe887767fbf99f83398c5ca3e42b4b6f","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €7.1m (million) as of June 30, 2025 following successful completion of €9.7m private placement in February 2025","length":128,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash runway secured until Q2 2026 considering the US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million, both received in July 2025","length":183,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Recent advances on flagship product pipeline:","length":45,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"BioChaperone® Lispro read out positive Phase 3 top-line data in China in people with Type 2 Diabetes and results in Type 1 Diabetes expected in Q4 2025","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"BioChaperone® and BC CagriSema: business priority given to establishing partnerships, while generating additional differentiated data","length":133,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"AdoShell®:","length":10,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"proof-of-concept established on insulin-secreting stem cells and priority given to find a partner","length":97,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"submission of the clinical trial application with human islets now expected in Q3 2026","length":86,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":183,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":477,"olTyp...